| Bioactivity | RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcinoma (MTC) with IC50s of 3.6 μM (3 days) and 3.0 μM (6 days) against TT(C634R) MTC[1]. |
| Name | RET-IN-25 |
| CAS | 2965703-02-8 |
| Formula | C22H17N3O5S |
| Molar Mass | 435.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. La Monica G, et al. Design and Synthesis of Novel Thieno [3, 2-c] quinoline Compounds with Antiproliferative Activity on RET-Dependent Medullary Thyroid Cancer Cells[J]. ACS Omega, 2023.. . . |
RET-IN-25
CAS: 2965703-02-8 F: C22H17N3O5S W: 435.45
RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcino
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.